Atara Biotherapeutics (ATRA) Getting Somewhat Favorable Press Coverage, Accern Reports
News headlines about Atara Biotherapeutics (NASDAQ:ATRA) have trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Atara Biotherapeutics earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.3008271143036 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern’s analysis:
- Zacks: Brokerages Anticipate Atara Biotherapeutics, Inc. (ATRA) to Announce -$1.03 Earnings Per Share (americanbankingnews.com)
- Insider Selling: Atara Biotherapeutics, Inc. (ATRA) CEO Sells 4,400 Shares of Stock (americanbankingnews.com)
- Retrophin (RTRX) & Atara Biotherapeutics (ATRA) Critical Survey (americanbankingnews.com)
- Atara Biotherapeutics, Inc. (ATRA) EVP Christopher Haqq Sells 6,000 Shares (americanbankingnews.com)
- Atara Biotherapeutics, Inc. (ATRA) Earns Buy Rating from Canaccord Genuity (americanbankingnews.com)
Several research firms recently issued reports on ATRA. BidaskClub cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Canaccord Genuity set a $47.00 target price on Atara Biotherapeutics and gave the stock a “buy” rating in a research note on Monday, August 7th. ValuEngine cut Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, June 27th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a research note on Thursday, June 22nd. Three research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $25.50.
Shares of Atara Biotherapeutics (NASDAQ:ATRA) traded up 0.64% during mid-day trading on Friday, reaching $15.65. 192,906 shares of the company’s stock traded hands. The firm’s market capitalization is $478.25 million. Atara Biotherapeutics has a 12-month low of $11.80 and a 12-month high of $23.00. The stock has a 50-day moving average price of $14.71 and a 200 day moving average price of $15.84.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.94) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.05). Analysts anticipate that Atara Biotherapeutics will post ($3.89) EPS for the current fiscal year.
In other news, EVP Mitchall G. Clark sold 3,021 shares of the stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $14.33, for a total transaction of $43,290.93. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Christopher Haqq sold 6,000 shares of the stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $14.92, for a total transaction of $89,520.00. Following the transaction, the executive vice president now owns 362,080 shares in the company, valued at $5,402,233.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,909 shares of company stock worth $810,518. Insiders own 16.10% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Atara Biotherapeutics (ATRA) Getting Somewhat Favorable Press Coverage, Accern Reports” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/24/atara-biotherapeutics-atra-getting-somewhat-favorable-press-coverage-accern-reports.html.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.